Hollings Home  
 
Harry A Drabkin, MD
Professor of Medicine
Hematology/Oncology
College of Medicine
MUSC

Email: drabkin@musc.edu
 
       Print This Page
       
 
 


 

Harry A Drabkin, MD

Return to Search Page  

Research Interest:

Dr. Drabkin has made important contributions to cancer cell biology in the areas of acute leukemia, kidney cancer and lung cancer. He discovered the AML1/RUNX1 - ETO fusion in the acute myelogenous leukemia 8;21 translocation and the hereditary kidney cancer gene, TRC8, subsequently elucidating its function as an E3-ubiquitin ligase targeting the pre-SREBP transcription factors that regulate cholesterol biosynthesis. In lung cancer, he discovered the secreted semaphorin, SEMA3F, and found that it functions as a potent tumor suppressor frequently deleted or downregulated in this disease. Clinically, he is recognized in the treatment of metastatic kidney cancer and is active in NCI, industry and investigator-initiated clinical trials.

Honors:
Gilbreth Chair in Clinical Oncology, Hollings Cancer Center, Medical University of South Carolina

Selected Publications:

1.Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Muñoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, Haura EB. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS One. .11(1):e0147344, 2016. PMID: 26789630 PMCID: PMC4720447
View in: PubMed

2.Michel Ortega RM, Drabkin HA. Nivolumab in renal cell carcinoma. Expert Opin Biol Ther. .15(7):1049-60, 2015. PMID: 26038957
View in: PubMed

3.Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopoulos J, Kanesvaran R, Lauer R, Starodub A, Hauke R, Sweeney CJ, Hahn NM, Sonpavde G, Richey S, Breen T, Kremmidiotis G, Leske A, Doolin E, Bibby DC, Simpson J, Iglesias J, Hutson T. A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. Clin Cancer Res. .21(15):3420-7, 2015. PMID: 25788492 PMCID: PMC4526387
View in: PubMed

4.Skvarova Kramarzova K, Fiser K, Mejstrikova E, Rejlova K, Zaliova M, Fornerod M, Drabkin HA, van den Heuvel-Eibrink MM, Stary J, Trka J, Starkova J. Homeobox gene expression in acute myeloid leukemia is linked to typical underlying molecular aberrations. J Hematol Oncol. .7:94, 2014. PMID: 25539595 PMCID: PMC4310032
View in: PubMed

5.Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. .33(13):1430-7, 2014. PMID: 25452452
View in: PubMed

6.Nasarre P, Gemmill RM, Drabkin HA. The emerging role of class-3 semaphorins and their neuropilin receptors in oncology. Onco Targets Ther. .7:1663-87, 2014. PMID: 25285016 PMCID: PMC4181631
View in: PubMed

7.Kato T, Franconi CP, Sheridan MB, Hacker AM, Inagakai H, Glover TW, Arlt MF, Drabkin HA, Gemmill RM, Kurahashi H, Emanuel BS. Analysis of the t(3;8) of hereditary renal cell carcinoma: a palindrome-mediated translocation. Cancer Genet. .207(4):133-40, 2014. PMID: 24813807 PMCID: PMC4102306
View in: PubMed

8.Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs. .32(1):178-87, 2013. PMID: 24242861 PMCID: PMC4560460
View in: PubMed

9.Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH, Drabkin HA. Neuropilin-2 Is upregulated in lung cancer cells during TGF-ß1-induced epithelial-mesenchymal transition. Cancer Res. .73(23):7111-21, 2013. PMID: 24121493 PMCID: PMC3926507
View in: PubMed

10.Roche J, Nasarre P, Gemmill R, Baldys A, Pontis J, Korch C, Guilhot J, Ait-Si-Ali S, Drabkin H. Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers (Basel). .5(2):334-56, 2013. PMID: 24216980 PMCID: PMC3730320
View in: PubMed

11.Chakravarty S, Lai WC, Zou Y, Drabkin HA, Gemmill RM, Simon GR, Chin SH, Chen RT. Multiplexed specific label-free detection of NCI-H358 lung cancer cell line lysates with silicon based photonic crystal microcavity biosensors. Biosens Bioelectron. .43:50-5, 2012. PMID: 23274197 PMCID: PMC3594323
View in: PubMed

12.Drabkin HA, Gemmill RM. Cholesterol and the development of clear-cell renal carcinoma. Curr Opin Pharmacol. .12(6):742-50, 2012. PMID: 22939900
View in: PubMed

13.Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. .31(1):115-25, 2012. PMID: 22415798
View in: PubMed

14.Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G, Gemmill RM, Drabkin HA, Lloyd GK, Neuteboom ST, McConkey DJ, Palladino MA, Spear MA. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. .30(6):2303-17, 2011. PMID: 22080430
View in: PubMed

15.Petit A, Ragu C, Soler G, Ottolenghi C, Schluth C, Radford-Weiss I, Schneider-Maunoury S, Callebaut I, Dastugue N, Drabkin HA, Bernard OA, Romana S, Penard-Lacronique V. Functional analysis of the NUP98-CCDC28A fusion protein. Haematologica. .97(3):379-87, 2011. PMID: 22058212 PMCID: PMC3291592
View in: PubMed

16.Starkova J, Gadgil S, Qiu YH, Zhang N, Hermanova I, Kornblau SM, Drabkin HA. Up-regulation of homeodomain genes, DLX1 and DLX2, by FLT3 signaling. Haematologica. .96(6):820-8, 2011. PMID: 21357706 PMCID: PMC3105643
View in: PubMed

17.Starkova J, Zamostna B, Mejstrikova E, Krejci R, Drabkin HA, Trka J. HOX gene expression in phenotypic and genotypic subgroups and low HOXA gene expression as an adverse prognostic factor in pediatric ALL. Pediatr Blood Cancer. .55(6):1072-82, 2010. PMID: 20672366
View in: PubMed

18.Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. .300(1):66-78, 2010. PMID: 20980099 PMCID: PMC3337721
View in: PubMed

19.Flaig TW, Costa LJ, Gustafson DL, Breaker K, Schultz MK, Crighton F, Kim FJ, Drabkin H. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br J Cancer. .103(6):796-801, 2010. PMID: 20823888 PMCID: PMC2966634
View in: PubMed

20.Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology. .78(5-6):340-7, 2010. PMID: 20733337
View in: PubMed

21.Sheridan MB, Kato T, Haldeman-Englert C, Jalali GR, Milunsky JM, Zou Y, Klaes R, Gimelli G, Gimelli S, Gemmill RM, Drabkin HA, Hacker AM, Brown J, Tomkins D, Shaikh TH, Kurahashi H, Zackai EH, Emanuel BS. A palindrome-mediated recurrent translocation with 3:1 meiotic nondisjunction: the t(8;22)(q24.13;q11.21). Am J Hum Genet. .87(2):209-18, 2010. PMID: 20673865 PMCID: PMC2917714
View in: PubMed

22.Drabkin HA. Pazopanib and anti-VEGF therapy. Open Access J Urol. .2:35-40, 2010. PMID: 24198612 PMCID: PMC3818876
View in: PubMed

23.Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. .116(5):1272-80, 2010. PMID: 20082451
View in: PubMed

24.Lee JP, Brauweiler A, Rudolph M, Hooper JE, Drabkin HA, Gemmill RM. The TRC8 ubiquitin ligase is sterol regulated and interacts with lipid and protein biosynthetic pathways. Mol Cancer Res. .8(1):93-106, 2010. PMID: 20068067 PMCID: PMC3086825
View in: PubMed

25.Nasarre P, Potiron V, Drabkin H, Roche J. Guidance molecules in lung cancer. Cell Adh Migr. .4(1):130-45, 2010. PMID: 20139699 PMCID: PMC2852570
View in: PubMed

26.Drabkin HA, Gemmill RM. Obesity, cholesterol, and clear-cell renal cell carcinoma (RCC). Adv Cancer Res. .107:39-56, 2010. PMID: 20399960
View in: PubMed

27.Roche J, Drabkin H. Letter from the guest editors. Cell Adh Migr. .4(1):94-5, 2010. PMID: 20549881 PMCID: PMC2852564
View in: PubMed

28.Kakihana M, Ohira T, Chan D, Webster RB, Kato H, Drabkin HA, Gemmill RM. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. J Thorac Oncol. .4(12):1455-65, 2009. PMID: 20009910 PMCID: PMC2796578
View in: PubMed

29.Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, Garcia-Manero G, Chen W, Medeiros LJ, Bueso-Ramos CE. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer. .115(20):4737-44, 2009. PMID: 19637342 PMCID: PMC4199225
View in: PubMed

30.Stagg HR, Thomas M, van den Boomen D, Wiertz EJ, Drabkin HA, Gemmill RM, Lehner PJ. The TRC8 E3 ligase ubiquitinates MHC class I molecules before dislocation from the ER. J Cell Biol. .186(5):685-92, 2009. PMID: 19720873 PMCID: PMC2742190
View in: PubMed

31.Gimelli S, Beri S, Drabkin HA, Gambini C, Gregorio A, Fiorio P, Zuffardi O, Gemmill RM, Giorda R, Gimelli G. The tumor suppressor gene TRC8/RNF139 is disrupted by a constitutional balanced translocation t(8;22)(q24.13;q11.21) in a young girl with dysgerminoma. Mol Cancer. .8:52, 2009. PMID: 19642973 PMCID: PMC2727492
View in: PubMed

32.Arighi CN, Liu H, Natale DA, Barker WC, Drabkin H, Blake JA, Smith B, Wu CH. TGF-beta signaling proteins and the Protein Ontology. BMC Bioinformatics. .10 Suppl 5:S3, 2009. PMID: 19426460 PMCID: PMC2679403
View in: PubMed

33.Cappuzzo F, Varella-Garcia M, Rossi E, Gajapathy S, Valente M, Drabkin H, Gemmill R. MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib. J Thorac Oncol. .4(4):472-8, 2009. PMID: 19204574 PMCID: PMC2774779
View in: PubMed

34.Miura N, Sato R, Tsukamoto T, Shimizu M, Kabashima H, Takeda M, Takahashi S, Harada T, West JE, Drabkin H, Mejia JE, Shiota G, Murawaki Y, Virmani A, Gazdar AF, Oshimura M, Hasegawa J. A noncoding RNA gene on chromosome 10p15.3 may function upstream of hTERT. BMC Mol Biol. .10:5, 2009. PMID: 19187532 PMCID: PMC2661890
View in: PubMed

35.Clarhaut J, Gemmill RM, Potiron VA, Ait-Si-Ali S, Imbert J, Drabkin HA, Roche J. ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells. Neoplasia. .11(2):157-66, 2009. PMID: 19177200 PMCID: PMC2631140
View in: PubMed

36.Andreeff M, Ruvolo V, Gadgil S, Zeng C, Coombes K, Chen W, Kornblau S, Barón AE, Drabkin HA. HOX expression patterns identify a common signature for favorable AML. Leukemia. .22(11):2041-7, 2008. PMID: 18668134 PMCID: PMC2676170
View in: PubMed

37.Potiron VA, Roche J, Drabkin HA. Semaphorins and their receptors in lung cancer. Cancer Lett. .273(1):1-14, 2008. PMID: 18625544 PMCID: PMC2630718
View in: PubMed

38.Ballonoff A, Kavanagh B, Nash R, Drabkin H, Trotter J, Costa L, Rabinovitch R. Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review. Acta Oncol. .47(5):962-70, 2008. PMID: 17906981
View in: PubMed

39.Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist. .12(12):1404-15, 2007. PMID: 18165617
View in: PubMed

40.Baselga J, Tabernero J. Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet. J Clin Oncol. .25(29):4516-8, 2007. PMID: 17876011
View in: PubMed

41.Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. .25(29):4536-41, 2007. PMID: 17876014
View in: PubMed

42.Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, Roche J, Drabkin HA. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Res. .67(18):8708-15, 2007. PMID: 17875711
View in: PubMed

43.Poland KS, Azim M, Folsom M, Goldfarb R, Naeem R, Korch C, Drabkin HA, Gemmill RM, Plon SE. A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma. Genes Chromosomes Cancer. .46(9):805-12, 2007. PMID: 17539022
View in: PubMed

44.Ryan CW, Goldman BH, Lara PN, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. .25(22):3296-301, 2007. PMID: 17664477
View in: PubMed

45.Costa LJ, Gemmill RM, Drabkin HA. Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology. .69(3):596-602, 2007. PMID: 17382186
View in: PubMed

46.Brauweiler A, Lorick KL, Lee JP, Tsai YC, Chan D, Weissman AM, Drabkin HA, Gemmill RM. RING-dependent tumor suppression and G2/M arrest induced by the TRC8 hereditary kidney cancer gene. Oncogene. .26(16):2263-71, 2006. PMID: 17016439
View in: PubMed

47.Xavier AC, Marshall C, La Rosa FG, Costa LJ, Drabkin H, Crawford ED. Woman with a papillary pulmonary lesion and a complex renal cyst. Oncology (Williston Park). .20(11):1437-9, 1443, 2006. PMID: 17112003
View in: PubMed

48.Su X, Drabkin H, Clappier E, Morgado E, Busson M, Romana S, Soulier J, Berger R, Bernard OA, Lavau C. Transforming potential of the T-cell acute lymphoblastic leukemia-associated homeobox genes HOXA13, TLX1, and TLX3. Genes Chromosomes Cancer. .45(9):846-55, 2006. PMID: 16804919
View in: PubMed

49.Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC, Hong L, Lai C, Cameron RB, Gemmill RM, Drabkin HA, Dubinett SM. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. .66(10):5338-45, 2006. PMID: 16707460
View in: PubMed

50.Clarhaut J, Roche J, Drabkin HA. Semaphorins in lung cancer. J Thorac Oncol. .1(3):203-4, 2006. PMID: 17409857
View in: PubMed

51.Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. .66(2):944-50, 2006. PMID: 16424029
View in: PubMed

52.Kusy S, Potiron V, Zeng C, Franklin W, Brambilla E, Minna J, Drabkin HA, Roche J. Promoter characterization of Semaphorin SEMA3F, a tumor suppressor gene. Biochim Biophys Acta. .1730(1):66-76, 2005. PMID: 16005989
View in: PubMed

53.Gemmill RM, Zhou M, Costa L, Korch C, Bukowski RM, Drabkin HA. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer. .92(12):2266-77, 2005. PMID: 15956968 PMCID: PMC2361810
View in: PubMed

54.Nasarre P, Constantin B, Drabkin HA, Roche J. [Semaphorins and cancers : an up 'dating']. Med Sci (Paris). .21(6-7):641-7, 2005. PMID: 15985208
View in: PubMed

55.Gemmill RM, Lee JP, Chamovitz DA, Segal D, Hooper JE, Drabkin HA. Growth suppression induced by the TRC8 hereditary kidney cancer gene is dependent upon JAB1/CSN5. Oncogene. .24(21):3503-11, 2005. PMID: 15735686
View in: PubMed

56.Kusy S, Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill RM, Constantin B, Drabkin HA, Roche J. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia. .7(5):457-65, 2005. PMID: 15967098 PMCID: PMC1501157
View in: PubMed

57.Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, Roche J. Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia. .7(2):180-9, 2005. PMID: 15802023 PMCID: PMC1501131
View in: PubMed

58.Roche J, Zeng C, Barón A, Gadgil S, Gemmill RM, Tigaud I, Thomas X, Drabkin HA. Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics. Leukemia. .18(6):1059-63, 2004. PMID: 15085154
View in: PubMed

59.Kusy S, Funkelstein L, Bourgais D, Drabkin H, Rougon G, Roche J, Castellani V. Redundant functions but temporal and regional regulation of two alternatively spliced isoforms of semaphorin 3F in the nervous system. Mol Cell Neurosci. .24(2):409-18, 2003. PMID: 14572462
View in: PubMed

60.Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, Brambilla E, Zeng C, Baron A, Bemis L, Erickson P, Wilder E, Rustgi A, Kitajewski J, Gabrielson E, Bremnes R, Franklin W, Drabkin HA. WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci U S A. .100(18):10429-34, 2003. PMID: 12937339 PMCID: PMC193578
View in: PubMed

61.Lantuéjoul S, Constantin B, Drabkin H, Brambilla C, Roche J, Brambilla E. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol. .200(3):336-47, 2003. PMID: 12845630
View in: PubMed

62.Nasarre P, Constantin B, Rouhaud L, Harnois T, Raymond G, Drabkin HA, Bourmeyster N, Roche J. Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading. Neoplasia. .5(1):83-92, 2003. PMID: 12659673 PMCID: PMC1502125
View in: PubMed

63.de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, Drabkin H, Hiebert SW, Klug CA. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol. .22(15):5506-17, 2002. PMID: 12101243 PMCID: PMC133929
View in: PubMed

64.Gemmill RM, Bemis LT, Lee JP, Sozen MA, Baron A, Zeng C, Erickson PF, Hooper JE, Drabkin HA. The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway. Oncogene. .21(22):3507-16, 2002. PMID: 12032852
View in: PubMed

65.Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA, Franklin WA. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol. .20(10):2417-28, 2002. PMID: 12011119
View in: PubMed

66.Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, Roy L, Zeng C, Baron A, Hunger SP, Varella-Garcia M, Gemmill R, Brizard F, Brizard A, Roche J. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia. .16(2):186-95, 2002. PMID: 11840284
View in: PubMed

67.Roche J, Drabkin H, Brambilla E. Neuropilin and its ligands in normal lung and cancer. Adv Exp Med Biol. .515:103-14, 2002. PMID: 12613547
View in: PubMed

68.Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, Roche J, Drabkin H, Lerman MI, Gazdar AF, Minna JD. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci U S A. .98(24):13954-9, 2001. PMID: 11717452 PMCID: PMC61148
View in: PubMed

69.Varella-Garcia M, Hogan CJ, Odom LF, Murata-Collins JL, Ai H, Chen L, Richkind K, Paskulin G, Andreeff M, Brizard A, McGavran L, Gemmill RM, Berger R, Drabkin HA. Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting. Leukemia. .15(9):1408-14, 2001. PMID: 11516101
View in: PubMed

70.Ueda M, Gemmill RM, West J, Winn R, Sugita M, Tanaka N, Ueki M, Drabkin HA. Mutations of the beta- and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer. .85(1):64-8, 2001. PMID: 11437403 PMCID: PMC2363927
View in: PubMed

71.Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, Helfrich B, Bunn P, Roche J, Brambilla E, Rosell R, Gemmill RM, Drabkin HA. Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci U S A. .97(23):12776-81, 2000. PMID: 11070089 PMCID: PMC18840
View in: PubMed

72.Brambilla E, Constantin B, Drabkin H, Roche J. Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration. Am J Pathol. .156(3):939-50, 2000. PMID: 10702410 PMCID: PMC1876858
View in: PubMed

73.Drabkin HA, West JD, Hotfilder M, Heng YM, Erickson P, Calvo R, Dalmau J, Gemmill RM, Sablitzky F. DEF-3(g16/NY-LU-12), an RNA binding protein from the 3p21.3 homozygous deletion region in SCLC. Oncogene. .18(16):2589-97, 1999. PMID: 10353602
View in: PubMed

74.Gemmill RM, West JD, Boldog F, Tanaka N, Robinson LJ, Smith DI, Li F, Drabkin HA. The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proc Natl Acad Sci U S A. .95(16):9572-7, 1998. PMID: 9689122 PMCID: PMC21380
View in: PubMed

75.Paskulin GA, Philips G, Morgan R, Sandberg A, Richkind K, Borovik C, McGavran L, Rabinovich N, Dietz-Band J, Erickson P, Drabkin H, Varella-Garcia M. Pre-clinical evaluation of probes to detect t(8;21) AML minimal residual disease by fluorescence in situ hybridization. Genes Chromosomes Cancer. .21(2):144-51, 1998. PMID: 9491326
View in: PubMed

76.David G, Abbas N, Stevanin G, Dürr A, Yvert G, Cancel G, Weber C, Imbert G, Saudou F, Antoniou E, Drabkin H, Gemmill R, Giunti P, Benomar A, Wood N, Ruberg M, Agid Y, Mandel JL, Brice A. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet. .17(1):65-70, 1997. PMID: 9288099
View in: PubMed

77.Boldog F, Gemmill RM, West J, Robinson M, Robinson L, Li E, Roche J, Todd S, Waggoner B, Lundstrom R, Jacobson J, Mullokandov MR, Klinger H, Drabkin HA. Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. Hum Mol Genet. .6(2):193-203, 1997. PMID: 9063739
View in: PubMed

78.Erickson PF, Dessev G, Lasher RS, Philips G, Robinson M, Drabkin HA. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood. .88(5):1813-23, 1996. PMID: 8781439
View in: PubMed

79.Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, Swanton M, Waggoner B, Fishel R, Franklin W, Gemmill R, Drabkin H. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene. .12(6):1289-97, 1996. PMID: 8649831
View in: PubMed

80.Erickson PF, Robinson M, Owens G, Drabkin HA. The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor. Cancer Res. .54(7):1782-6, 1994. PMID: 8137293
View in: PubMed

81.Boldog FL, Gemmill RM, Wilke CM, Glover TW, Nilsson AS, Chandrasekharappa SC, Brown RS, Li FP, Drabkin HA. Positional cloning of the hereditary renal carcinoma 3;8 chromosome translocation breakpoint. Proc Natl Acad Sci U S A. .90(18):8509-13, 1993. PMID: 7690964 PMCID: PMC47386
View in: PubMed

82.Nucifora G, Begy CR, Erickson P, Drabkin HA, Rowley JD. The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1. Proc Natl Acad Sci U S A. .90(16):7784-8, 1993. PMID: 8395054 PMCID: PMC47227
View in: PubMed

83.Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood. .80(7):1825-31, 1992. PMID: 1391946
View in: PubMed